Hagan P L, Halpern S E, Dillman R O, Shawler D L, Johnson D E, Chen A, Krishnan L, Frincke J, Bartholomew R M, David G S
J Nucl Med. 1986 Mar;27(3):422-7.
Studies were performed to determine the effect of tumor size on the incorporation of radiolabeled monoclonal antitumor antibodies (MoAbs) into human tumors growing in nude mice. The colon tumors ranged in size from 0.03-1.6 g, the melanoma from 0.1 to 6.7 g, and the lymphoma from 0.06 to 10.2 g. Indium-111 was primarily used as the radiolabel, however, both 125I and 111In were used as tracers for the MoAb in one experiment. The per g radiopharmaceutical uptake by tumors was inversely proportional to tumor size when tumor specific MoAb was administered. This finding was independent of the radiolabel and was demonstrable when the mice bore two tumors of differing size. When the MoAb was not specific for the tumor, the data were less well defined and a statistically significant correlation with size did not occur. These data are strong evidence for a decrease in per g uptake of labeled tumor specific antibodies as tumors increase in size.
开展了多项研究,以确定肿瘤大小对放射性标记的单克隆抗肿瘤抗体(MoAbs)掺入裸鼠体内生长的人类肿瘤的影响。结肠肿瘤大小在0.03 - 1.6克之间,黑色素瘤在0.1至6.7克之间,淋巴瘤在0.06至10.2克之间。主要使用铟 - 111作为放射性标记,不过,在一项实验中,125I和111In都用作MoAb的示踪剂。当给予肿瘤特异性MoAb时,每克肿瘤的放射性药物摄取量与肿瘤大小成反比。这一发现与放射性标记无关,并且当小鼠携带两个大小不同的肿瘤时也可得到证明。当MoAb对肿瘤无特异性时,数据的界定不太清晰,且与大小没有统计学上的显著相关性。这些数据有力地证明,随着肿瘤增大,每克标记的肿瘤特异性抗体的摄取量会减少。